Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the National Advisory Council for Complementary and Alternative Medicine (NACCAM) meeting.
The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.
A portion of the meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussion could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Advisory Council for Complementary and Alternative Medicine.
Date: September 10, 2004.
Closed: 8:30 a.m. to 2 p.m.
Agenda: To review and evaluate grant applications and/or proposals.
Open: 2 p.m. to adjournment.
Agenda: The agenda includes Opening Remarks by Director, NCCAM, NCCAM's second five-year Strategic Plan and other business of the Council.
Place: Neuroscience Conference Center, 6001 Executive Boulevard, Conference Rooms C and D, Rockville, MD 20892.
Contact Person: Jane F. Kinsel, Ph.D., M.B.A., Executive Secretary, National Center for Complementary and Alternative Medicine, National Institutes of Health, 6707 Democracy Blvd., Suite 401, Bethesda, MD 20892, (301) 496-6701.
The public comments session is scheduled from 4:30-5 p.m. Each speaker will be permitted 5 minutes for their presentation. Interested individuals and representatives of organizations are requested to notify Dr. Jane Kinsel, National Center for Complementary and Alternative Medicine, NIH, 6707 Democracy Boulevard, Suite 401, Bethesda, Maryland 20892, (301) 496-6701, Fax: (301) 480-0087. Letters of intent to present comments, along with a brief description of the organization represented, should be received no later than 5 p.m., on August 31, 2004. Only one representative of an organization may present oral comments. Any person attending the meeting who does not request an opportunity to speak in advance of the meeting may be considered for oral presentation, if time permits, and at the discretion of the Chairperson. In addition, written comments may be submitted to Dr. Jane Kinsel at the address listed above up to ten calendar days (September 20, 2004) following the meeting.
Copies of the meeting agenda and the roster of members will be furnished upon request by contacting Dr. Jane Kinsel, Executive Secretary, NACCAM, National Institutes of Health, 6707 Democracy Boulevard, Suite 401, Bethesda, Maryland 20892, (301) 496-6701, Fax (301) 480-0087, or via e-mail at email@example.com.Start Signature
Dated: August 11, 2004.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy, NIH.
[FR Doc. 04-19074 Filed 8-19-04; 8:45 am]
BILLING CODE 4140-01-M